Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €32.64 EUR
Change Today -0.80 / -2.39%
Volume 0.0
ZA7 On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 2:09 AM 07/30/15 All times are local (Market data is delayed by at least 15 minutes).

zafgen inc (ZA7) Snapshot

Open
€32.60
Previous Close
€33.44
Day High
€32.64
Day Low
€32.60
52 Week High
03/20/15 - €48.06
52 Week Low
08/4/14 - €12.86
Market Cap
877.8M
Average Volume 10 Days
50.0
EPS TTM
--
Shares Outstanding
26.9M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ZAFGEN INC (ZA7)

Related News

No related news articles were found.

zafgen inc (ZA7) Related Businessweek News

No Related Businessweek News Found

zafgen inc (ZA7) Details

Zafgen, Inc., a biopharmaceutical company, focuses on the development of therapeutics for patients suffering from obesity and obesity-related disorders. Its lead product candidate includes Beloranib, an injection, which is in Phase III clinical trials for the treatment of obesity and hyperphagia in Prader-Willi Syndrome patients; that has completed Phase II clinical trials for the treatment of hypothalamic injury-associated obesity, including craniopharyngioma-associated obesity; and which is in Phase IIb clinical trials for the treatment of severe obesity in the general population. The company is also developing ZGN-839, a methionine aminopeptidase 2 inhibitor, which is in preclinical studies to reduce the severity of nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and abdominal obesity. Zafgen, Inc. was founded in 2005 and is headquartered in Boston, Massachusetts.

26 Employees
Last Reported Date: 05/14/15
Founded in 2005

zafgen inc (ZA7) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: $425.0K
President
Total Annual Compensation: $195.4K
Chief Financial Officer
Total Annual Compensation: $297.9K
Chief Medical Officer
Total Annual Compensation: $407.0K
Chief Commercial Officer
Total Annual Compensation: $328.8K
Compensation as of Fiscal Year 2014.

zafgen inc (ZA7) Key Developments

Zafgen, Inc. Presents at BIO International Convention 2015, Jun-16-2015 03:30 PM

Zafgen, Inc. Presents at BIO International Convention 2015, Jun-16-2015 03:30 PM. Venue: Pennsylvania Convention Center, Philadelphia, Pennsylvania, United States. Speakers: Thomas E. Hughes, Chief Executive Officer and Director.

Zafgen Completes Enrollment of U.S. Phase 3 Trial of Beloranib in Prader-Willi Syndrome

Zafgen, Inc. announced that the company has completed enrollment of ZAF-311, also known as the Beloranib Efficacy Safety and Tolerability in Prader-Willi syndrome (bestPWS) study, a Phase 3 clinical trial of beloranib for the treatment of patients with Prader-Willi syndrome (PWS). The objective of the study is to evaluate the efficacy and safety of beloranib in PWS patients over 6 months of randomized treatment, followed by a six-month open label extension. The trial includes 108 patients with PWS enrolled across 15 sites in the U.S.; the planned enrollment target number was 102 patients. PWS is the most common known genetic cause of life-threatening obesity and results in constant and unrelenting hunger that drives patients with PWS to engage in problematic hunger-related behaviors, known as hyperphagia, and to gain excessive weight. As a result, many of those affected become morbidly obese and suffer significant mortality. There is currently no cure or effective treatment for PWS. BestPWS is a six-month trial consisting of randomized, double-blind, placebo controlled, twice-weekly subcutaneous injections of 1.8 mg or 2.4 mg of beloranib or placebo in 108 patients with PWS. The primary efficacy endpoints for this trial are hyperphagia-related behaviors and body weight. Secondary endpoints include changes in total body fat mass, LDL-c, HDL-c, C-reactive protein (CRP) which is a marker of systemic inflammation, among others, and quality of life. At the time of screening, patients enrolled in the trial are, on average, 20 years old, morbidly obese (BMI 40 kg/m2), roughly equal number of males and females, and have a hyperphagia total score consistent with moderate to severe hyperphagia. Thus, the enrolled population is representative of the general PWS population and what was intended for this Phase 3 clinical trial.

Zafgen, Inc. Announces Executive Appointments

Zafgen, Inc. announced the appointments of Nerissa Kreher, M.D., M.S., M.B.A., as Global Head of Medical Affairs, and Kevin P. Malobisky, Ph.D., M.S., R.A.C., as Global Head of Regulatory. Most recently, Dr. Kreher was the Global Clinical Development Lead, Neonatology, at Shire. Previously, she held several roles at Alexion Pharmaceuticals and Enobia Pharma, where she became the Executive Medical Director, Medical Affairs Franchise Lead, Metabolic Diseases, and was responsible for the global medical affairs metabolic disease program. Most recently, Dr. Malobisky was a Senior Regulatory Consultant working with the Harte Group. Prior to that, he spent 14 years with Sanofi, where he held positions of increasing seniority in Regulatory Affairs and ultimately served as Associate Vice President, Global Regulatory Affairs, a position comprised of two roles: Regional Head, United States and Canada, and Global Head, Fibrosis & Cardiovascular.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ZA7:GR €32.64 EUR -0.80

ZA7 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ZA7.
View Industry Companies
 

Industry Analysis

ZA7

Industry Average

Valuation ZA7 Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 4.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ZAFGEN INC, please visit www.zafgen.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.